Longview Asset Management Has Trimmed General Dynamics (GD) Position By $1.22 Million; Anthera Pharmaceuticals (ANTH) Shorts Raised By 39.04%

May 23, 2018 - By Dolores Ford

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Logo

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) had an increase of 39.04% in short interest. ANTH’s SI was 1.47M shares in May as released by FINRA. Its up 39.04% from 1.06M shares previously. With 2.88M avg volume, 1 days are for Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s short sellers to cover ANTH’s short positions. The stock decreased 3.40% or $0.01 during the last trading session, reaching $0.273. About 401,278 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 90.50% since May 23, 2017 and is downtrending. It has underperformed by 102.05% the S&P500.

Longview Asset Management Llc decreased General Dynamics Corp (GD) stake by 0.02% reported in 2017Q4 SEC filing. Longview Asset Management Llc sold 6,023 shares as General Dynamics Corp (GD)’s stock rose 9.09%. The Longview Asset Management Llc holds 33.32M shares with $6.78 billion value, down from 33.33M last quarter. General Dynamics Corp now has $61.06 billion valuation. The stock increased 0.58% or $1.19 during the last trading session, reaching $205.56. About 971,751 shares traded. General Dynamics Corporation (NYSE:GD) has risen 19.18% since May 23, 2017 and is uptrending. It has outperformed by 7.63% the S&P500.

Another recent and important Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” on May 18, 2018.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $7.14 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

Among 7 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Anthera Pharmaceuticals had 21 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Monday, January 22. On Monday, June 26 the stock rating was maintained by Jefferies with “Hold”. The rating was initiated by SunTrust on Wednesday, September 9 with “Buy”. The firm earned “Buy” rating on Friday, February 19 by Jefferies. The rating was maintained by Piper Jaffray on Thursday, December 29 with “Overweight”. The firm has “Sell” rating given on Monday, March 12 by Piper Jaffray. H.C. Wainwright initiated it with “Buy” rating and $10 target in Friday, July 8 report. The rating was initiated by Citigroup with “Buy” on Thursday, September 17. Jefferies maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) on Tuesday, February 13 with “Hold” rating. The firm has “Hold” rating given on Tuesday, March 6 by Jefferies.

Investors sentiment decreased to 1.07 in 2017 Q4. Its down 0.01, from 1.08 in 2017Q3. It worsened, as 43 investors sold GD shares while 328 reduced holdings. 108 funds opened positions while 290 raised stakes. 229.66 million shares or 10.22% less from 255.81 million shares in 2017Q3 were reported. Diversified Tru stated it has 1,530 shares or 0.02% of all its holdings. Edgar Lomax Va reported 174,989 shares. 28,322 are held by Advantus Capital Management. Balyasny Asset Mngmt Lc owns 5,100 shares for 0% of their portfolio. Cohen Lawrence B holds 1,660 shares or 0.21% of its portfolio. South Dakota Invest Council accumulated 0.08% or 18,000 shares. Northwestern Mutual Wealth Mngmt has 0.02% invested in General Dynamics Corporation (NYSE:GD) for 13,240 shares. Evanson Asset Management Limited Liability Company accumulated 1,299 shares. Moreover, Nuveen Asset Management Ltd Llc has 0.18% invested in General Dynamics Corporation (NYSE:GD). Arrowgrass (Us) Limited Partnership holds 0.1% or 50,000 shares in its portfolio. Tru Department Mb Savings Bank N A reported 1.26% of its portfolio in General Dynamics Corporation (NYSE:GD). Ardevora Asset Mngmt Llp holds 0.61% or 99,429 shares. Legal & General Grp Public Limited Company accumulated 1.20M shares or 0.18% of the stock. Aperio Ltd Liability Com stated it has 195,734 shares or 0.21% of all its holdings. Moors Cabot Inc holds 0.11% or 4,191 shares.

Analysts await General Dynamics Corporation (NYSE:GD) to report earnings on July, 25. They expect $2.56 EPS, up 4.49% or $0.11 from last year’s $2.45 per share. GD’s profit will be $760.40M for 20.07 P/E if the $2.56 EPS becomes a reality. After $2.65 actual EPS reported by General Dynamics Corporation for the previous quarter, Wall Street now forecasts -3.40% negative EPS growth.

Since February 14, 2018, it had 0 insider buys, and 8 selling transactions for $8.28 million activity. Roualet Mark C. also sold $814,050 worth of General Dynamics Corporation (NYSE:GD) on Tuesday, February 27. Shares for $389,574 were sold by KEANE JOHN M. Another trade for 5,977 shares valued at $1.34 million was sold by Whited Gary L. 9,304 shares were sold by CASEY JOHN PATRICK, worth $2.00 million. 5,210 shares valued at $1.15 million were sold by LYLES LESTER L on Friday, February 23. Shares for $899,843 were sold by Johnson S. Daniel.

Among 22 analysts covering General Dynamics Corporation (NYSE:GD), 14 have Buy rating, 2 Sell and 6 Hold. Therefore 64% are positive. General Dynamics Corporation had 79 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of General Dynamics Corporation (NYSE:GD) earned “Buy” rating by Jefferies on Friday, October 13. The stock has “Neutral” rating by Citigroup on Thursday, January 25. The stock has “Buy” rating by Argus Research on Tuesday, August 2. The firm earned “Buy” rating on Monday, October 23 by Robert W. Baird. JP Morgan downgraded General Dynamics Corporation (NYSE:GD) on Wednesday, December 16 to “Neutral” rating. Wells Fargo maintained General Dynamics Corporation (NYSE:GD) rating on Tuesday, February 13. Wells Fargo has “Buy” rating and $240.0 target. The rating was maintained by Stifel Nicolaus on Thursday, April 26 with “Hold”. On Sunday, October 8 the stock rating was maintained by RBC Capital Markets with “Buy”. The rating was maintained by Citigroup on Monday, October 9 with “Neutral”. Bernstein maintained it with “Market Perform” rating and $156 target in Wednesday, February 24 report.

General Dynamics Corporation (NYSE:GD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.